Premium
Nerve growth factor gene delivery: Animal models to clinical trials
Author(s) -
Tuszynski Mark H.
Publication year - 2007
Publication title -
developmental neurobiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.716
H-Index - 129
eISSN - 1932-846X
pISSN - 1932-8451
DOI - 10.1002/dneu.20510
Subject(s) - neurotrophic factors , neuroscience , nerve growth factor , neurotrophin , biology , nervous system , brain derived neurotrophic factor , disease , central nervous system , bioinformatics , medicine , pathology , receptor , biochemistry
Abstract Cell death is the final common pathway of cognitive decline in Alzheimer's disease (AD). Nervous system growth factors, or neurotrophic factors, are substances naturally produced in the nervous system that support neuronal survival during development and influence neuronal function throughout adulthood. Notably, in animal models, including primates, neurotrophic factors prevent neuronal death after injury and can reverse spontaneous neuronal atrophy in aging. Thus, neurotrophic factor therapy has the potential to prevent or reduce ongoing cell loss in disorders such as AD. The main challenge in clinical testing of neurotrophic factors has been their delivery to the brain in sufficient doses to impact cell function, while restricting their delivery to specific sites to prevent adverse effects from broad distribution. This article reviews progress in evaluating the therapeutic potential of growth factors, from early animal models to human clinical trials currently underway in AD. © 2007 Wiley Periodicals, Inc. Develop Neurobiol, 2007